List of Excipients in Branded Drug BETAGAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	BETAGAN	levobunolol hydrochloride	0023-4385	BENZALKONIUM CHLORIDE
Allergan Inc	BETAGAN	levobunolol hydrochloride	0023-4385	EDETATE DISODIUM
Allergan Inc	BETAGAN	levobunolol hydrochloride	0023-4385	HYDROCHLORIC ACID
Allergan Inc	BETAGAN	levobunolol hydrochloride	0023-4385	POLYVINYL ALCOHOL

Betagan Excipient Strategy and Commercial Opportunities for Levobunolol Ophthalmic Solution

Last updated: August 11, 2026

Betagan is a topical ophthalmic solution containing levobunolol hydrochloride, a nonselective beta-adrenergic blocker used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Its established formulation uses benzalkonium chloride, citrate buffering, sodium chloride, water for injection, and pH adjustment with sodium hydroxide. The strongest commercial opportunities are preservative-free delivery, improved ocular tolerability, differentiated multidose packaging, and combination products rather than new chemical-entity exclusivity.

What is Betagan and which excipients does it contain?

Betagan is marketed in 0.25% and 0.5% levobunolol hydrochloride ophthalmic solution strengths. The formulation is an aqueous, preserved eye drop. The labeled inactive ingredients include benzalkonium chloride, sodium citrate, citric acid, sodium chloride, and water for injection. Sodium hydroxide may be used for pH adjustment. The labeled pH range is approximately 5.5 to 7.5, supporting levobunolol hydrochloride solubility and ocular tolerability (FDA, 2012; DailyMed, 2024).

Component	Functional role	Commercial significance
Levobunolol hydrochloride	Active pharmaceutical ingredient	Water-soluble beta blocker for intraocular-pressure reduction
Benzalkonium chloride	Antimicrobial preservative	Enables multidose packaging but may contribute to ocular-surface irritation
Citric acid and sodium citrate	Buffer system	Controls pH and supports chemical stability
Sodium chloride	Tonicity agent	Helps approximate physiologic osmolality
Water for injection	Vehicle	Supports sterile ophthalmic delivery
Sodium hydroxide	pH adjustment	Allows final pH correction during manufacture

The core formulation is technically conventional. Its commercial weakness is the use of benzalkonium chloride in a chronic-use glaucoma product. Long-term exposure to benzalkonium chloride has been associated with ocular-surface toxicity, including epithelial disruption, inflammation, tear-film instability, and discomfort, particularly in patients using multiple preserved ophthalmic products (Baudouin et al., 2010).

What excipient functions are most important for levobunolol eye drops?

The excipient strategy must balance solubility, pH, comfort, sterility, preservative performance, container compatibility, and dose uniformity.

Solubility and pH control

Levobunolol is supplied as the hydrochloride salt, which supports aqueous formulation. The formulation should maintain a pH that preserves solubility without creating excessive stinging or instability. A citrate buffer is commercially practical because it is familiar to regulators and ophthalmic manufacturers.

A lower buffer capacity may improve ocular comfort after instillation, but insufficient buffering can allow pH drift during storage or after repeated container opening. A stronger buffer may improve stability while increasing irritation. The optimal design is likely a low-capacity citrate system combined with tightly controlled manufacturing water quality and container closure performance.

Tonicity adjustment

Sodium chloride provides tonicity control. Alternative tonicity agents, including glycerin, mannitol, or boric acid systems, could support a differentiated formulation, but substitution would require compatibility and ocular-tolerability studies.

Tonicity should be evaluated together with pH and buffer capacity. A formulation that is nominally isotonic can still cause discomfort if its pH, viscosity, preservative concentration, or drop volume is unfavorable.

Preservative selection

Benzalkonium chloride is the principal excipient opportunity. It is effective, inexpensive, and widely used in multidose ophthalmic products. Its disadvantage is chronic ocular-surface exposure.

Potential alternatives include:

• Polyquaternium-1, commonly used in preserved ophthalmic products.
• Oxidative preservative systems, such as stabilized oxychloro complexes.
• Peroxide-based systems, subject to complete neutralization before ocular exposure.
• Preservative-free unit-dose packaging.
• Preservative-free multidose pumps using non-return valves or sterile barrier technology.

Each alternative creates a different regulatory and commercial profile. A new preservative system may require more compatibility and microbiological testing than a preservative-free presentation, while unit-dose packaging increases manufacturing, logistics, and waste costs.

Viscosity modification

Low-level viscosity enhancement could increase ocular residence time and reduce drainage through the nasolacrimal duct. Candidate excipients include hydroxypropyl methylcellulose, hydroxypropyl cellulose, carbomers, polyethylene glycol systems, and hyaluronic-acid derivatives.

The tradeoff is substantial. Higher viscosity can improve retention but may cause blurred vision, sticky sensation, slower drop formation, or inconsistent dosing. Levobunolol is commonly used once or twice daily depending on the product and patient response, so a modest viscosity increase could support adherence if it does not impair visual quality.

Surfactants and wetting agents

Surfactants are not central to the existing Betagan formulation because the hydrochloride salt is water soluble. They could be considered for container wetting, surface adsorption control, or suspension-based alternatives, but surfactants would add ocular-tolerability and extractables risks without an obvious commercial need for the current solution product.

What formulation patents could protect a Betagan follow-on product?

The active ingredient and basic ophthalmic solution are mature technologies. A defensible intellectual-property strategy would focus on formulation, delivery, packaging, or manufacturing claims.

Preservative-free formulation patents

Potential claim elements include:

• A sterile aqueous levobunolol solution without benzalkonium chloride.
• A specific pH and buffer-capacity range.
• A defined osmolality range.
• A stabilizing excipient combination.
• A multidose container maintaining sterility after repeated actuation.
• Limits on degradation products during long-term storage.

A claim directed only to “levobunolol ophthalmic solution” would likely be vulnerable because of longstanding public disclosure and generic products. Patent strength would improve if the formulation produced a demonstrated stability, tolerability, or delivery advantage.

Low-preservative formulations

A reduced-benzalkonium formulation could target patients who require chronic therapy but cannot tolerate conventional preserved drops. The patent case would need to distinguish the concentration, buffer system, container, or preservative-performance profile from existing products.

Viscous or mucoadhesive formulations

A formulation that increases ocular residence time while maintaining optical clarity could support method and composition claims. Useful data would include:

• Ocular-surface residence time.
• Intraocular-pressure reduction over a full dosing interval.
• Drop-size consistency.
• Visual-blur duration.
• Comparative tolerability against preserved aqueous levobunolol.
• Reduced dosing frequency or improved adherence.

Combination products

Levobunolol could be combined with agents such as dorzolamide, brinzolamide, brimonidine, or prostaglandin analogs. Combination products face substantial development challenges, including pH compatibility, chemical stability, preservative burden, dosing rationale, and clinical justification.

A combination patent could cover the composition, fixed-dose regimen, use in patients inadequately controlled on monotherapy, or a specific preservative-free delivery platform.

When does Betagan lose exclusivity and what is the Orange Book status?

Betagan is a mature small-molecule ophthalmic product. Its original regulatory exclusivity period has expired, and levobunolol ophthalmic solutions have been subject to generic competition. The principal regulatory pathway is an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

Exclusivity category	Betagan assessment
New chemical entity exclusivity	Expired
Five-year NCE exclusivity	Not commercially relevant to the current product
Three-year clinical-investigation exclusivity	Expired for the original product
Orphan-drug exclusivity	Not applicable to the broad glaucoma indication
Pediatric exclusivity	No current commercial barrier
Biosimilar pathway	Not applicable because levobunolol is a small molecule
Generic pathway	ANDA pathway
Paragraph IV exposure	Possible only against any unexpired, properly listed Orange Book patent

The Orange Book remains the controlling source for listed patents, therapeutic-equivalence codes, and current approval status. For a mature product such as Betagan, the principal competitive barriers are manufacturing quality, sterile fill-finish capacity, preservative-free packaging, customer conversion, and supply reliability rather than statutory exclusivity (FDA, 2024a).

Which companies are challenging or competing with Betagan?

Generic competition has historically included levobunolol hydrochloride ophthalmic solution products from multiple ANDA sponsors. The relevant competitive set includes:

• Generic levobunolol 0.25% ophthalmic solution.
• Generic levobunolol 0.5% ophthalmic solution.
• Timolol maleate ophthalmic products.
• Betaxolol ophthalmic products.
• Carteolol ophthalmic products in markets where approved.
• Prostaglandin analogs such as latanoprost, bimatoprost, and travoprost.
• Alpha-agonist and carbonic-anhydrase-inhibitor products.
• Fixed-dose glaucoma combinations.

The commercial comparison is unfavorable for an unmodified Betagan generic because timolol and prostaglandin analogs have broad physician familiarity and extensive generic supply. A differentiated levobunolol product would need to compete on ocular-surface tolerability, dosing convenience, preservative-free delivery, or supply performance.

What FDA regulatory status applies to a new Betagan formulation?

A conventional generic ophthalmic solution may qualify for an ANDA if it demonstrates pharmaceutical equivalence and bioequivalence under the applicable FDA standards. A materially different formulation may require a 505(b)(2) application, especially if it changes:

• The preservative system.
• The dosage form.
• The dosing frequency.
• The delivery device.
• The concentration.
• The route or mechanism of delivery.
• The clinical performance of the product.

A preservative-free version in the same dosage form may still require more than a simple generic approach if the formulation or container changes affect sterility assurance, dosing, stability, or labeling. The regulatory pathway depends on the extent of formulation and device differences.

The FDA Inactive Ingredient Database can support excipient selection by showing prior use levels in approved ophthalmic products. It does not replace formulation-specific safety, stability, preservative-effectiveness, container-closure, and manufacturing studies (FDA, 2024b).

What manufacturing and intellectual-property barriers affect Betagan opportunities?

Sterile manufacturing

Ophthalmic solutions require validated sterile processing, microbial-control systems, container-closure integrity, and low-particulate manufacturing. Preservative-free multidose products require higher control over the device and repeated-use contamination risk.

The most difficult manufacturing step may not be solution compounding. It may be sterile filling into a low-cost, reliable delivery system that produces consistent drops and maintains sterility throughout labeled use.

Container-closure systems

A preservative-free product needs a container that prevents microbial ingress. Relevant technologies include:

• Unit-dose blow-fill-seal ampoules.
• Multidose pumps with one-way valves.
• Sterile venting systems.
• Tip-barrier technologies.
• Metered-dose ophthalmic devices.

Device patents may create more meaningful protection than composition patents. A company that owns a validated preservative-free multidose platform can potentially use it across several glaucoma molecules.

Extractables and leachables

Plastic containers, elastomers, coatings, and pump components may introduce extractables or leachables. Levobunolol formulation development should evaluate adsorption, sorption, pH drift, preservative loss, and degradation products over the full shelf life.

Supply-chain barriers

The active ingredient is mature and may be available from multiple sources, but sterile ophthalmic manufacturing capacity is more constrained. Commercial launch risk includes:

• Dependence on a single API supplier.
• Limited preservative-free fill-finish capacity.
• Device component shortages.
• Batch rejection from sterility or particulate failures.
• Inadequate cold-chain or light-protection controls where applicable.
• High packaging costs for unit-dose formats.

How strong is the patent estate for a Betagan follow-on product?

The legacy Betagan patent estate is unlikely to provide a meaningful barrier to ordinary levobunolol ophthalmic-solution entry. A new entrant would need to create its own protection around a differentiated platform.

Opportunity	Likely patent strength	Commercial attractiveness
Conventional preserved aqueous generic	Low	Low to moderate
Lower-benzalkonium formulation	Moderate if supported by data	Moderate
Preservative-free unit-dose product	Moderate	Moderate to high
Preservative-free multidose device	Moderate to high	High
Viscosity-enhanced solution	Moderate	Moderate
Sustained-release ocular delivery	High if clinically validated	High, but development-intensive
Fixed-dose combination	Moderate to high	High if clinically differentiated
Novel suspension or implant	Potentially high	High risk and high cost

Patent value will depend on claim scope, unexpected results, freedom-to-operate analysis, and the ability to demonstrate a clinically relevant advantage. A broad formulation patent without comparative ocular-tolerability or stability data would face validity and obviousness challenges.

What licensing deals could create commercial value?

The most practical licensing structures involve platform assets rather than the Betagan brand itself. Potential targets include:

• A preservative-free multidose ophthalmic device.
• A sterile unit-dose manufacturing platform.
• A mucoadhesive excipient system.
• A validated low-irritation preservative technology.
• Regional rights to levobunolol or glaucoma combinations.
• Contract development and manufacturing partnerships with ophthalmic specialists.

A licensee could combine an established levobunolol ANDA or 505(b)(2) development program with a device owner’s packaging technology. The value proposition would be stronger if the platform is already used in FDA-approved ophthalmic products and has documented compatibility with beta blockers.

What generic launch scenarios exist for Betagan?

Scenario 1: Commodity generic launch

A sponsor launches a conventional 0.25% or 0.5% preserved solution. Pricing is pressured by multiple suppliers, and differentiation is limited. This is the lowest-risk but least attractive strategy.

Scenario 2: Preservative-free unit-dose launch

A sponsor targets patients with ocular-surface disease, chronic polypharmacy, contact-lens intolerance, or prior preservative-related discomfort. Unit-dose packaging supports a clear label claim but increases manufacturing and distribution costs.

Scenario 3: Preservative-free multidose launch

This is the strongest commercial formulation opportunity. The product could command a premium if the device is easy to use, maintains sterility, and produces a consistent drop. Device reliability and human-factors performance are critical.

Scenario 4: Combination-product launch

A fixed-dose levobunolol combination could target patients requiring more than one mechanism of action. The development burden is higher, but combination products can improve adherence and reduce the number of preserved bottles used daily.

Scenario 5: Sustained-release delivery

A depot, insert, gel, or other extended-release system could reduce dosing frequency. This would require substantially more clinical development and would compete with established long-acting glaucoma therapies.

How does Betagan compare with timolol and prostaglandin analogs?

Attribute	Levobunolol, Betagan	Timolol	Prostaglandin analogs
Drug class	Nonselective beta blocker	Nonselective beta blocker	Prostaglandin receptor agonist
Generic maturity	High	High	High for leading products
Preservative-free opportunity	Strong	Strong	Strong
Typical dosing burden	Once or twice daily depending on product	Often once or twice daily	Commonly once daily
Ocular-surface differentiation	Mainly formulation-driven	Mainly formulation-driven	Formulation and class effects both matter
Systemic beta-blocker concerns	Relevant	Relevant	Generally different safety profile
Best commercial strategy	Preservative-free or device differentiation	Scale and price	Adherence, tolerability, and premium delivery

Betagan has limited strategic value as a plain preserved generic. Its opportunity is greater as a platform product for patients who need beta-blocker therapy but have poor tolerance of conventional preserved drops or require a more convenient delivery system.

What revenue exposure and market opportunity should investors assess?

Revenue depends on five variables:

1. The size of the levobunolol-treated patient population.
2. The share of patients using preserved versus preservative-free products.
3. The reimbursement premium available for differentiated packaging.
4. The number of generic suppliers at launch.
5. The cost of goods for sterile filling and device assembly.

A commodity generic is likely to experience rapid price erosion. A preservative-free or device-enabled product can defend a higher net price, but only if the product secures formulary access and demonstrates a recognizable benefit.

Commercial value is more likely to arise from a portfolio strategy. A company could use one preservative-free delivery platform for levobunolol, timolol, carbonic anhydrase inhibitors, and fixed-dose combinations. That approach spreads device-development costs and creates broader licensing potential.

Key Takeaways

• Betagan contains levobunolol hydrochloride in a preserved aqueous ophthalmic solution.
• Its principal excipients are benzalkonium chloride, citrate buffer, sodium chloride, and water for injection.
• Benzalkonium chloride is the clearest formulation weakness and the strongest excipient-based opportunity.
• A conventional generic faces limited patent protection and substantial price competition.
• Preservative-free unit-dose and multidose systems offer better differentiation.
• Device, sterility, compatibility, and manufacturing patents may be more valuable than basic composition claims.
• Levobunolol is a small molecule, so biosimilar risk does not apply.
• Any new formulation that materially changes the dosage form, device, or clinical profile may require a 505(b)(2) strategy rather than a straightforward ANDA.
• The most attractive commercial model is a preservative-free ophthalmic platform that can be applied across multiple glaucoma products.

FAQs

Can benzalkonium chloride be removed from Betagan without changing the active ingredient?

Yes. A preservative-free levobunolol formulation can retain levobunolol hydrochloride while changing the container and sterility strategy. The key development issue is maintaining sterility throughout the labeled in-use period.

Is a preservative-free Betagan product likely to receive a premium price?

It can receive a premium if it demonstrates lower ocular-surface burden, supports chronic-use patients, and secures reimbursement. Unit-dose packaging may limit margin unless manufacturing is highly efficient.

Would a low-viscosity gel improve levobunolol commercial value?

A modest viscosity increase could improve ocular residence and dosing convenience. Excessive viscosity could cause blurred vision, poor drop formation, and lower patient acceptance.

Does Betagan have biosimilar competition?

No. Levobunolol is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways rather than the biosimilar framework.

What is the most defensible patent strategy for a new levobunolol product?

The strongest strategy would combine composition claims with claims covering a preservative-free multidose device, defined stability performance, controlled drop size, and improved ocular tolerability supported by comparative data.

References

1. Baudouin, C., Labbe, A., Liang, H., Pauly, A., & Brignole-Baudouin, F. (2010). Preservatives in eye drops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 29(4), 312-334. https://doi.org/10.1016/j.preteyeres.2010.03.001

2. DailyMed. (2024). Betagan: Levobunolol hydrochloride ophthalmic solution prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2012). Betagan label: Levobunolol hydrochloride ophthalmic solution. https://www.accessdata.fda.gov/

4. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

5. U.S. Food and Drug Administration. (2024b). Inactive Ingredient Database. https://www.fda.gov/drugs/drug-approvals-and-databases/inactive-ingredient-database-used-approved-drug-products